[Recommendations for clinical practice: use of TEP-FDG in cancer of the esophagus, stomach, colon and rectum, anal canal, large intestine, pancreas and bile ducts, liver and endocrine tumors (digestive system)].
Bourguet
Patrick
P
Centre Eugène Marquis, Rennes.
Planchamp
François
F
Monteil
Jacques
J
Metges
Jean-Philippe
JP
Mitry
Emmanuel
E
Tubiana-Mathieu
Nicole
N
D001005:Anus Neoplasms / Q000000981:diagnostic imaging; D001650:Bile Duct Neoplasms / Q000000981:diagnostic imaging; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging; D004067:Digestive System Neoplasms / Q000000981:diagnostic imaging*; D004701:Endocrine Gland Neoplasms / Q000000981:diagnostic imaging; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging; D006801:Humans; D007420:Intestine, Large / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000000981:diagnostic imaging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000592:standards*; D019275:Radiopharmaceuticals; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18